Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes ...(king statement can be guaranteed and act...)

Date:5/26/2009

king statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen's products after they are on the market. Amgen's business may be impacted by government investigations, litigation and products liability claims. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected b
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years